Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies -
- Allergan continues five ongoing Phase 3 studies with DURYSTA™ to support further potential FDA label enhancement and rest of the world approvals -
DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for intracameral administration. With this approval, DURYSTA™ becomes the first intracameral, biodegradable sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Posted In: AGN